Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 19 | 5 | +0,46 % | ||
| BIONTECH | 8 | 13 | -2,92 % | ||
| IMMUNITYBIO | 8 | 3 | -13,13 % | ||
| LENZ THERAPEUTICS | 7 | 5 | -18,09 % | ||
| NEUROGENE | 7 | 1 | -2,30 % | ||
| ABSCI | 7 | - | +2,89 % | ||
| BIOAGE LABS | 7 | - | -18,56 % | ||
| COMPASS PATHWAYS | 6 | 11 | -4,27 % | ||
| ALNYLAM PHARMACEUTICALS | 4 | 9 | -0,41 % | ||
| HARROW | 4 | 4 | +3,50 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:31 | Absci Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 21:28 | LENZ Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 21:28 | Absci Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 21:17 | Neurogene Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 21:12 | Absci Corporation: Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results | 1 | GlobeNewswire (USA) | ||
| 21:10 | Gilead-Deal untermauert Potenzial: Clear Street bestätigt Kaufempfehlung für Cullinan Oncology | 3 | Investing.com Deutsch | ||
| 21:10 | LENZ Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 21:10 | Mizuho hebt Kursziel für Enliven Therapeutics nach CML-Daten auf 45 US-Dollar an | 2 | Investing.com Deutsch | ||
| 21:10 | Oppenheimer bestätigt "Outperform"-Rating für BioAge Labs mit Kursziel von 60 US-Dollar | 1 | Investing.com Deutsch | ||
| 21:08 | BioAge Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 21:06 | Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation | 2 | Investing.com | ||
| 21:06 | Alnylam stock price target maintained at $460 by BofA Securities | 2 | Investing.com | ||
| 21:06 | Morgan Stanley reiterates Alnylam stock Equalweight rating at $360 | 3 | Investing.com | ||
| 21:06 | Mizuho raises Enliven Therapeutics price target to $45 on CML data | 1 | Investing.com | ||
| 21:06 | Oppenheimer reiterates Outperform on BioAge Labs stock at $60 | 1 | Investing.com | ||
| 21:05 | Ascendis Pharma A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21:05 | Neurogene Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20:46 | Morgan Stanley senkt Kursziel für Compass Pathways trotz Fortschritten bei Depressionsbehandlung | 1 | Investing.com Deutsch | ||
| 20:42 | Morgan Stanley cuts Compass Pathways stock price target on TRD progress | 2 | Investing.com | ||
| 20:31 | ImmunityBio stock price crash: buy the dip or sell the rip? | 8 | iNVEZZ.com |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.